» Articles » PMID: 36512260

Artificial Intelligence-Based Prediction of Recurrence After Curative Resection for Colorectal Cancer from Digital Pathological Images

Abstract

Background: To develop an artificial intelligence-based model to predict recurrence after curative resection for stage I-III colorectal cancer from digitized pathological slides.

Patients And Methods: In this retrospective study, 471 consecutive patients who underwent curative resection for stage I-III colorectal cancer at our institution from 2004 to 2015 were enrolled, and 512 randomly selected tiles from digitally scanned images of hematoxylin and eosin-stained tumor tissue sections were used to train a convolutional neural network. Five-fold cross-validation was used to validate the model. The association between recurrence and the model's output scores were analyzed in the test cohorts.

Results: The area under the receiver operating characteristic curve of the cross-validation was 0.7245 [95% confidence interval (CI) 0.6707-0.7783; P < 0.0001]. The score successfully classified patients into those with better and worse recurrence free survival (P < 0.0001). Multivariate analysis revealed that a high score was significantly associated with worse recurrence free survival [odds ratio (OR) 1.857; 95% CI 1.248-2.805; P = 0.0021], which was independent from other predictive factors: male sex (P = 0.0238), rectal cancer (P = 0.0396), preoperative abnormal carcinoembryonic antigen (CEA) level (P = 0.0216), pathological T3/T4 stage (P = 0.0162), and pathological positive lymph node metastasis (P < 0.0001).

Conclusions: The artificial intelligence-based prediction model discriminated patients with a high risk of recurrence. This approach could help decision-makers consider the benefits of adjuvant chemotherapy.

Citing Articles

Towards understanding cancer dormancy over strategic hitching up mechanisms to technologies.

Yang S, Seo J, Choi J, Kim S, Kuk Y, Park K Mol Cancer. 2025; 24(1):47.

PMID: 39953555 PMC: 11829473. DOI: 10.1186/s12943-025-02250-9.


Whole slide image based prognosis prediction in rectal cancer using unsupervised artificial intelligence.

Zhou X, Dai J, Lu Y, Zhao Q, Liu Y, Wang C BMC Cancer. 2024; 24(1):1523.

PMID: 39696090 PMC: 11658449. DOI: 10.1186/s12885-024-13292-5.


Machine learning based prediction of recurrence after curative resection for rectal cancer.

Jeon Y, Kim Y, Jeon J, Nam K, Hwang T, Kim K PLoS One. 2023; 18(12):e0290141.

PMID: 38100485 PMC: 10723658. DOI: 10.1371/journal.pone.0290141.

References
1.
Hohenberger W, Weber K, Matzel K, Papadopoulos T, Merkel S . Standardized surgery for colonic cancer: complete mesocolic excision and central ligation--technical notes and outcome. Colorectal Dis. 2008; 11(4):354-64. DOI: 10.1111/j.1463-1318.2008.01735.x. View

2.
Heald R, Ryall R . Recurrence and survival after total mesorectal excision for rectal cancer. Lancet. 1986; 1(8496):1479-82. DOI: 10.1016/s0140-6736(86)91510-2. View

3.
Andre T, Meyerhardt J, Iveson T, Sobrero A, Yoshino T, Souglakos I . Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised, phase 3 trials. Lancet Oncol. 2020; 21(12):1620-1629. PMC: 7786835. DOI: 10.1016/S1470-2045(20)30527-1. View

4.
Cohen R, Taieb J, Fiskum J, Yothers G, Goldberg R, Yoshino T . Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials. J Clin Oncol. 2020; 39(6):642-651. PMC: 8189604. DOI: 10.1200/JCO.20.01600. View

5.
Taniguchi H, Nakamura Y, Kotani D, Yukami H, Mishima S, Sawada K . CIRCULATE-Japan: Circulating tumor DNA-guided adaptive platform trials to refine adjuvant therapy for colorectal cancer. Cancer Sci. 2021; 112(7):2915-2920. PMC: 8253296. DOI: 10.1111/cas.14926. View